PROMETH PLAIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prometh Plain, and what generic alternatives are available?
Prometh Plain is a drug marketed by Actavis Mid Atlantic and is included in one NDA.
The generic ingredient in PROMETH PLAIN is promethazine hydrochloride. There are twelve drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the promethazine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prometh Plain
A generic version of PROMETH PLAIN was approved as promethazine hydrochloride by ZYDUS PHARMS USA on November 18th, 2005.
Summary for PROMETH PLAIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 123 |
Clinical Trials: | 1 |
Patent Applications: | 2,660 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PROMETH PLAIN at DailyMed |
Recent Clinical Trials for PROMETH PLAIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
M.D. Anderson Cancer Center | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for PROMETH PLAIN
US Patents and Regulatory Information for PROMETH PLAIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actavis Mid Atlantic | PROMETH PLAIN | promethazine hydrochloride | SYRUP;ORAL | 085953-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |